Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response ; volume:167 ; number:2 ; day:18 ; month:3 ; year:2024 ; pages:243 ; date:4.2024
Journal of neuro-oncology ; 167, Heft 2 (18.3.2024), 243, 4.2024
- Creator
-
Bobholz, Samuel A.
Hoefs, Alisha
Hamburger, Jordyn
Lowman, Allison K.
Winiarz, Aleksandra
Duenweg, Savannah R.
Kyereme, Fitzgerald
Connelly, Jennifer
Coss, Dylan
Krucoff, Max
Banerjee, Anjishnu
LaViolette, Peter S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11060-024-04641-2
- URN
-
urn:nbn:de:101:1-2406292107217.755141393697
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bobholz, Samuel A.
- Hoefs, Alisha
- Hamburger, Jordyn
- Lowman, Allison K.
- Winiarz, Aleksandra
- Duenweg, Savannah R.
- Kyereme, Fitzgerald
- Connelly, Jennifer
- Coss, Dylan
- Krucoff, Max
- Banerjee, Anjishnu
- LaViolette, Peter S.
- SpringerLink (Online service)
Other Objects (12)
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Immune phenotypes predict survival in patients with glioblastoma multiforme
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Differential expression of microRNAs as predictors of glioblastoma phenotypes
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Immune phenotypes predict survival in patients with glioblastoma multiforme
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Differential expression of microRNAs as predictors of glioblastoma phenotypes
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Immune phenotypes predict survival in patients with glioblastoma multiforme
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Differential expression of microRNAs as predictors of glioblastoma phenotypes
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment